GMAB250117C30000
- 0.10
- 0.000.00%
Genmab Newsroom
Top Gap Ups and Downs on Friday: NVO, BABA, INFY and More
Bernstein Initiates Genmab(GMAB.US) With Hold Rating
Bernstein Upgrades Genmab to Market Perform, Lowers PT
Antibody Discovery Market Industry Forecast Report 2024-2035, Featuring Ablexis, ChemPartner, Creative Biolabs, GenScript, Genmab, Harbour BioMed, MabSilico, Nona Biosciences, WuXi Biologics and More
Analysts Conflicted on These Healthcare Names: Jazz Pharmaceuticals (JAZZ), Acadia Healthcare (ACHC) and Genmab (GMAB)
TD Cowen Maintains Genmab(GMAB.US) With Hold Rating
TD Cowen Reaffirms Their Hold Rating on Genmab (GMAB)
RBC Capital Keeps Their Buy Rating on Genmab A/S (0MGB)
Top Gap Ups and Downs on Thursday: CIEN, WBD, ADBE and More
Genmab to Hold 2024 R&D Update and ASH Data Review Meeting
City of Hope Reports Novel Immunotherapy in Clinical Trial Shows Promise for Patients With Relapsed or Difficult to Treat Chronic Lymphocytic Leukemia (CLL)
EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk
AbbVie And Genmab A/S Present Two Data Analyses From Clinical Trials Show Epcoritamab Induces Durable Complete Reponses As Monotherapy And Combination Treatment In Patients With Diffuse Large B-Cell Lymphoma; Results From Arm 1 Of The EPCORE NHL-2...
Genmab's Chronic Lymphocytic Leukemia Antibody Shows High Response Rates
Genmab Announces New Results From Phase 1b/2 EPCORE NHL-2 Trial
Genmab Announced Investigational Epcoritamab Combination Therapy Demonstrates High Response Rates In Clinical Trial Of Patients With Relapsed Or Refractory Follicular Lymphoma At ASH Meeting; Results Show 96% Overall Response Rate
6-K: Report of foreign private issuer (related to financial reporting)
Scancell Signs New Commercial License Deal With Genmab
Scancell Strikes Deal Worth up to $630m With Genmab | AIM:SCLP, OTC:SCNLF
Capital Increase in Genmab as a Result of Employee Warrant Exercise